MediWound to present ExcharEx data at wound care conferences

MediWound (MDWD)will present 10 scientific abstracts-including both oral and poster presentations-at two of the world’s premier wound care conferences: the Wound Healing Society and the Symposium on Advanced Wound Care Spring 2025, taking place April 30-May 3 in Grapevine, Texas. The presentations will feature new preclinical and clinical data on EscharEx, MediWound’s investigational enzymatic therapy for chronic wounds. The findings offer important insights into EscharEx’s multitargeted and selective mechanism of action, reinforcing the ongoing VALUE Phase III study in venous leg ulcers and supporting the planned clinical trial in diabetic foot ulcers. Key presentation highlights include: Wound Healing Society: New in vitro data highlighting EscharEx’ s multitargeted and selective proteolytic activity on non-viable tissue; Results from a novel hard-to-heal wound model demonstrating EscharEx’s superior debridement efficacy compared to collagenase SANTYL. Symposium on Advanced Wound Care; Overview of EscharEx’s mechanism of action, including in vitro studies and clinical findings from EscharEx and NexoBrid; Case studies highlighting EscharEx’s use in advanced DFUs and VLUs; Post-hoc analyses in DFUs and preliminary strategy for the planned clinical trial; Update on the VALUE Phase III study design and enrollment progress.